A greenfield approach to life sciences manufacturing

Expanding pharma’s capacity for the future with next-gen manufacturing

In recent years, greenfield builds—projects where facilities are constructed wholly or mostly from scratch—in the life sciences industry were often sidelined due to practical, financial, and strategic considerations.

But now, the expansion of advanced therapies, biologics, and precision medicine, as well as shifts in tax incentives and increased geopolitical pressures, is driving a surge in greenfield facility development. Is your organisation investing in the manufacturing facilities that will meet the needs of the future?

In this new POV, Life sciences greenfield build, Capgemini’s life sciences manufacturing experts explore how greenfield manufacturing projects are helping organisations scale up production capacity, meet evolving regulatory requirements, and integrate Pharma 4.0 initiatives.

Download the full POV to explore:

• The growth potential of greenfield manufacturing facilities
• Key challenges and strategic considerations for greenfield programs
• Strategies for optimising future greenfield builds
• How next-generation greenfield pharma plants stand apart from their predecessors
• The role of third-party partners in greenfield manufacturing projects

Learn why greenfield sites are fast becoming a requirement for reaching new levels of quality, resilience, and innovation for life sciences companies.